Lipid Treatment Assessment Project2

Epidemiologic data clearly demonstrate that risk of coronary heart disease is
directly correlated with levels of LDL cholesterol (LDL-C) and inversely
correlated with levels of HDL cholesterol (HDL-C)
During treatment of dylipidemia patients the main goal is to achieve the LDL-C
values as described in the cholesterol management guidelines in order to
decrease the cardiovascular risk.
Little is known about physicians* adherence to cholesterol management
guidelines in daily practice.
The first L-TAP study showed that only 38% of the treated patients achieved the
LDL-C goal

While this survey will provide information about mean LDL-C levels and the
percent of patients at LDL-C goals, the survey will also focus on HDL-C. A
primary objective of this survey is to assess the levels of HDL-C in treated
dyslipidemic patients, including patients attaining LDL-C treatment goals. This
will improve our understanding of the residual cardiovascular risk remaining in
patients treated with modern lipid modifying regimens by virtue of measuring
HDL-C levels in a large and geographically divers sample.

Patients will visit the hospital/ General physician just one visit.
During this visit Informed Consent will be documented, bloodpressure
measurement will be done, weight will be recorded and waist circumference will
be measured.
A blood sample will be taken, that will be analysed by a central lab.
All gathered data will be recorded in a Case Report Form.

The burden of the patients exists in a hospital visit where a bloodsample will
be taken. The risk will be the possibility of suffusion on the punture place.